Transthyretin-mediated amyloidosis (ATTR) is rare, progressive, and still undiagnosed.[1] At a featured session during Becker’s 16th Annual Meeting, a panel of cardiology and pharmacy leaders outlined both the scale of the problem and a practical playbook for health system administrators…
